Indometacinum
Hand-Foot Syndrome
National Taiwan University HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Hand-Foot Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adriamycin Swiss Cancer Institute | Phase 3 | BB |
Mecobalamin Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | B |
Celecoxib Affiliated Hospital of Qinghai University | Phase 3 | B |
Nicotine University of California, San Francisco | Phase 2 | CCC |
Tazarotene Dana-Farber Cancer Institute | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Indometacinum is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →